Biblio
1
Yang M, Safavi S, Woodward EL, Duployez N, Olsson-Arvidsson L, Ungerbäck J, Sigvardsson M, Zaliova M, Zuna J, Fioretos T, et al. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood. 2020.
C
Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, Ghosh S, Oburoglu L, Falqués-Costa A, Bellamkonda K, Ehinger M, Peña-Martínez P, Puente-Moncada N, et al. Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity. Blood Adv. 2023.
H
Modvig S, Wernersson R, Øbro NFriesgaard, Olsen LRønn, Christensen C, Rosthøj S, Degn M, Jürgensen GWullf, Madsen HO, Albertsen BKlug, et al. High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion. Mol Oncol. 2022.
T
Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, et al. Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2021.